Can-fite Biopharma Ltd.

Can-fite Biopharma Ltd. Israel

Can-fite Technologies Ltd.

Pnina Fishman

Shira Cohen

Ilan Cohn

Lea Madi

Kamel Khalili

Mordechai Farbstein

Sara Bar-Yehuda

Tatiana Reitblat

Sara Bar Yehuda

Guirguis Raouf

Inbal Itzhak

Motti Farbstein

Ilana Lorber

Provided is an A3 adenosine receptor (AAR) ligand for use in achieving at least one fat loss effect selected from: reducing weight of the subject; reducing body fat mass in the subject; treating obesity in the subject and inhibiting adipocytes proliferation in a subject. The disclosure also concerns pharmaceutical compositions, methods of treatment and kits comprising the AAR ligand.

A3 adenosine receptor ligand for use for achieving a fat loss effect

Provided is an AAR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Further provided is the use of AAR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, method of treating a condition associates with fat accumulation making use of the ligand and kits including pharmaceutical compositions including the ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. Further provided is the use of an AAR agonist, such as 2-Chloro-N-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (CI-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).

Method for treating fibrotic liver tissue using Cl-IB-MECA

Provided is an AAR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Further provided is the use of AAR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, method of treating a condition associates with fat accumulation making use of the ligand and kits including pharmaceutical compositions including the ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. Further provided is the use of an AAR agonist, such as 2-Chloro-N-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (Cl-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).

Method for treating NASH accompanied by fibrosis using Cl-IB-MECA

Provided is an Aadenosine receptor agonist (AAR agonist) for the preparation of a pharmaceutical composition for the treatment of a mammal subject having osteoarthritis (OA), as well as to a method for the treatment of OA in a mammal subject, the method includes administering to said subject in need of said treatment an amount of AAR agonist, the amount being effective to treat or prevent the development of OA. Preferred but not exclusive AAR agonists in accordance with the present subject matter are IB-MECA and Cl-IB-MECA. The AAR agonist may be administered in combination with another drug, such as Methotrexate (MTX). Also provided are pharmaceutical compositions for treatment of osteoarthritis including an amount of an AAR agonist.

Use of A3 adenosine receptor agonist in osteoarthritis treatment

The present disclosure provides an Aadenosine receptor (AAR) ligand for the treatment of sexual dysfunction. In some embodiments the AAR ligand is selected from an AAR agonist and AAR allosteric enhancer. The present disclosure also provides a method a method and pharmaceutical composition for treating a sexual dysfunction, the method comprises administering to a subject having the sexual dysfunction an amount of an Aadenosine receptor (AAR) ligand. In some embodiments, the AAR ligand is an AAR agonist and more specifically, IB-MECA.

A3 adenosine receptor ligands for use in treatment of a sexual dysfunction

The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an AAR agonist. A preferred AAR agonist disclosed herein is Cl-IB-MECA.

Method for inducing hepatocyte proliferation and uses thereof

Clinical finding shows that twice daily administrations of 2 mg of 1-deoxy-1-[N-(3-iodobenzyl)-adenin-9-yl]-N-methyl-&#x3b2;-D-ribofuronamide (IB-MECA) (total daily administration of 4 mg) to subjects having moderate to severe psoriasis, was significantly more effective in treatment of the psoriatic plaques than treatment of psoriasis at two administration doses of 1 mg or 4 mg (total daily doses of 2 or 8 mg, respectively). A pharmaceutical composition for the treatment of psoriasis includes as the active ingredient IB-MECA in an amount suitable for a total daily dose administration of about 4 mg. In one preferred embodiment, IB-MECA is administered twice a day to a subject in need of psoriasis treatment, the pharmaceutical composition including an administration dose of 2 mg.

[object Object]

The present disclosure provides the use of an A3R agonist, such as IB-MECA, for reducing in a subject, preferably, human subject, intra ocular pressure (IOP). Similarly, the invention provides a pharmaceutical composition and a method for reducing IOP in a subject making use of the AR agonist.

A3 adenoside receptor agonists for the reduction of intraocular pressure

Inflammatory state in a subject is assayed by determining the level of expression of Aadenosine receptor (AAR) in white blood cells (WBC), e.g. circulating WBCs, from the subject. A high level of expression of AAR is indicative of an inflammatory state in the subject. This assay can be used for determining the severity of inflammation in a subject and monitoring the efficacy of anti-inflammatory treatment. Also, the level of expression may be used for selecting patients to receive an anti-inflammatory treatment that comprises an AAR agonist.

Biological marker for inflammation

The present invention provides a method for treating dry eye condition in an individual comprising administrating to said individual an amount of Aadenosine receptor (AAR) agonist, the amount being effective to ameliorate symptoms of dry eye in the individual. In accordance with one embodiment, the dry eye condition is manifested by one or more ophthalmologic clinical symptoms selected from foreign body sensation, burning, itching, irritation, redness, eye pain, blurred vision, degraded vision and excessive tearing. A preferred ARAg in accordance with the invention is N-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA).

Treatment of dry eye conditions

The present invention concerns the use of an active ingredient selected from the group consisting of agonists of the adenosine receptor system, for inhibiting viral replication in cells. In particular, the invention provides a composition and method for inhibiting viral replication in cells, the method comprising presenting to the cells an effective amount of the active ingredient. According to one embodiment, the adenosine agonist is an A3 receptor agonist (A3RAg). The invention is particularly useful, for although not limited to, inhibiting the replication of HIV virus in human cells.

Use of an adenosine A3 receptor agonist for inhibition of viral replication

Individuals suffering from multiple sclerosis may be treated by administration of an A3 adenosine receptor agonist (A3RAg), such as APNEA, AB-MECA, IB-MECA or Cl-IB-MECA. The A3RAg is preferably administered orally with a pharmaceutically acceptable carrier.

Method for treatment of multiple sclerosis

The present invention concerns a method for the treatment of inflammatory arthritis, and in particular rheumatoid arthritis, by administering to the subject specific low dosages of N6-(3-iodobenzyl)-adenosine 5'-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)-adenosine-5&#x2032;-N-methyl-uronamide (CL-IB-MECA).

A3AR agonists for the treatment of inflammatory arthritis

Adenosine and active agent which interact with the adenosine system are used to treat conditions of weakened, immune system, as an anti-cancer therapy and for improving the therapeutic index of a variety of therapeutic drugs.

Growing community of inventors

Herzliya, Israel

Pnina Fishman